HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Donation after circulatory death donors in high-risk recipients undergoing bilateral lung transplantation: An ISHLT database registry analysis.

Abstract
Lung transplantation (LTx) using donation after circulatory death (DCD) donors has demonstrated equivalent outcomes compared to donation after brain dead (DBD) donors. However, data from the use of DCDs for high-risk (HR) recipients is limited. We performed a propensity match study to evaluate the impact of DCD transplantation on HR recipients. In addition, we assessed the effect of recipient profile (HR vs. non-HR) in DCDs and DBDs LTx. From 2009-2018, 1829 double lung transplants (DLTx) for HR recipients were identified. Of these, 131 were performed using DCD donors. There was no difference in survival between DCDs and DBDs among HR-DLTx recipients (p = 0.16). However, HR recipients had worse survival compared to non-HR recipients in DBD (p < 0.001) but not in DCD transplantation (p = 0.95). Our findings support that DCD lungs are appropriate for HR recipients and should not be considered inferior or higher-risk donors. Its use should be further stimulated rather than restricted.
AuthorsPedro Augusto Reck Dos Santos, Paulo José Zimermann Teixeira, Daniel Messias de Moraes Neto, Blake Langlais, Marcelo Cypel
JournalThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (J Heart Lung Transplant) Vol. 41 Issue 6 Pg. 712-715 (06 2022) ISSN: 1557-3117 [Electronic] United States
PMID35300913 (Publication Type: Journal Article)
CopyrightCopyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Topics
  • Brain Death
  • Death
  • Graft Survival
  • Humans
  • Lung Transplantation
  • Registries
  • Retrospective Studies
  • Tissue Donors
  • Tissue and Organ Procurement

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: